Source - RNS
RNS Number : 8912M
Advanced Oncotherapy PLC
19 October 2016


("Advanced Oncotherapy" or the "Company")


Harley Street planning permission granted


Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at a meeting held yesterday at Westminster City Council, planning permission for the Harley Street site was granted.


Commenting, Dr. Michael Sinclair, Executive Chairman and CEO of Advanced Oncotherapy, said: "The Harley Street Proton facility will make an important contribution to the advancement of next generation radiotherapy in the UK, and add even further lustre to the international reputation of the Howard de Walden Estate and the Harley Street Medical Area. Now that we are in a position to continue with the development, our partner, Howard de Walden Estates, plans to start work on the site as soon as possible. During the construction period every effort will be made to ensure minimal inconvenience to local residents."


Simon Baynham, Property Director of Howard de Walden Estates, commented: "The Estate is delighted that this new ground breaking technology will be coming to The Harley Street Medical Area. From a personal point of view I know many people who would have benefited from this new technology had it been available previously. Accordingly the sooner we get on and build it, the better."   ‎




Advanced Oncotherapy Plc

Dr. Michael Sinclair, Executive Chairman & CEO

Tel: +44 20 3617 8728

Nicolas Serandour, CFO & COO




Stockdale Securities (Nomad & Joint Broker)


Antonio Bossi / David Coaten

Tel: +44 20 7601 6100



Beaufort Securities (Joint Broker)


Jon Belliss / Elliot Hance

Tel: +44 20 7382 8300



Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001




About Advanced Oncotherapy Plc


Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.


Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.


The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers.


Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.





This information is provided by RNS
The company news service from the London Stock Exchange